Recent Finacing
Recent Raise
Kirilys Therapeutics is a preclinical-stage biopharmaceutical developing KRLS-017, a reversible oral small-molecule CDK7 inhibitor licensed from Ube, and partnering with D2G Oncology for genotype-linked in vivo efficacy models.
